Faye Su
Impact in
-
- Advanced Breast Cancer Therapies
- Cancer-related cognitive impairment studies
-
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
Papers in
-
- Advanced Breast Cancer Therapies 14
- Oncology 9
- Lung Cancer Research Studies 6
- Cancer Treatment and Pharmacology 3
- PARP inhibition in cancer therapy 1
- Co-authors
- Naveen Babbar (7 shared papers)Dennis J. Slamon (5 shared papers)Ronald Linnartz (4 shared papers)Neil A. O’Brien (4 shared papers)Dylan Conklin (4 shared papers)Tong Luo (3 shared papers)Samit Hirawat (4 shared papers)Martina S.J. McDermott (2 shared papers)
- Journals
- Cancer Research (10 papers)Annals of Oncology (2 papers)Veterinary Sciences (1 paper)Breast Cancer Research (1 paper)
- Partner nations
- United StatesSwitzerlandSpain
In The Last Decade
Faye Su
13 papers receiving 168 citations
Peers
Comparison fields: 5 of 22
- Pulmonary and Respiratory Medicine 133
- Oncology 92
- Cancer Research 50
- Genetics 21
- Molecular Biology 36
Countries citing papers authored by Faye Su
This map shows the geographic impact of Faye Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Faye Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Faye Su more than expected).
Fields of papers citing papers by Faye Su
This network shows the impact of papers produced by Faye Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Faye Su. The network helps show where Faye Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Faye Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 93 | |
| 2 | 2023 | 48 | |
| 3 | 2020 | 7 | |
| 4 | 2022 | 6 | |
| 5 | 2017 | 4 | |
| 6 | 2022 | 3 | |
| 7 | 2018 | 3 | |
| 8 | 2021 | 2 | |
| 9 | 2018 | 2 | |
| 10 | 2019 | 1 | |
| 11 | 2018 | 1 | |
| 12 | 2019 | 1 | |
| 13 | 2019 | 1 | |
| 14 | 2025 | 0 | |
| 15 | 2023 | 0 |
About Faye Su
Faye Su is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Epidemiology and Obstetrics and Gynecology, having authored 15 papers that have together received 172 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (14 papers), Lung Cancer Research Studies (6 papers), Cancer Genomics and Diagnostics (4 papers), Cancer Treatment and Pharmacology (3 papers), PARP inhibition in cancer therapy (1 paper), Gestational Diabetes Research and Management (1 paper), Breast Cancer Treatment Studies (1 paper) and Autophagy in Disease and Therapy (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (133 citations), Oncology (92 citations), Cancer Research (50 citations), Genetics (21 citations) and Molecular Biology (36 citations). Faye Su has collaborated with scholars based in United States, Switzerland and Spain. Frequent co-authors include Naveen Babbar, Dennis J. Slamon, Ronald Linnartz, Neil A. O’Brien, Dylan Conklin, Tong Luo, Samit Hirawat, Martina S.J. McDermott, Sara A. Hurvitz and Emmanuelle DiTomaso. Their work appears in journals such as Cancer Research, Annals of Oncology, Veterinary Sciences and Breast Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.